DuoGenic StemCells (ROCO:7607) Common Stock : NT$196.45 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells Common Stock?

DuoGenic StemCells's quarterly common stock stayed the same from Jun. 2023 (NT$196.45 Mil) to Dec. 2023 (NT$196.45 Mil) and stayed the same from Dec. 2023 (NT$196.45 Mil) to Jun. 2024 (NT$196.45 Mil).

DuoGenic StemCells's annual common stock increased from Dec. 2021 (NT$108.41 Mil) to Dec. 2022 (NT$146.41 Mil) and increased from Dec. 2022 (NT$146.41 Mil) to Dec. 2023 (NT$196.45 Mil).

DuoGenic StemCells Common Stock Historical Data

The historical data trend for DuoGenic StemCells's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells Common Stock Chart

DuoGenic StemCells Annual Data

Trend

Dec21

Dec22

Dec23

Common Stock

108.41

146.41

196.45

DuoGenic StemCells Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial			-	146.41	196.45	196.45	196.45

DuoGenic StemCells Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

DuoGenic StemCells Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN

Website

https://www.dgsc.com.tw

DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines